SystemLink, Inc Competitors

NanoString Technologies, a Bruker Company, is a provider of life science tools for translational research. The company's technology enables a wide variety of basic research and translational medicine applications. NanoString's products are based on a novel digital molecular barcoding technology invented at the Institute for Systems Biology (ISB) in Seattle under direction of Dr. Leroy Hood. The company was founded in 2003 with an exclusive license to develop and market the technology. In 2008, NanoString launched its first commercial instrument system and began international sales operations with its first multiplexed assays for gene expression analysis. In 2010, the company launched new applications for the system to support microRNA analysis and gene expression detection. In 2019, the company launched the GeoMx™ Digital Spatial Profiler enabling highly-multiplexed spatial profiling of RNA and protein targets in a variety of sample types, including FFPE tissue sections. In 2022, the company launched CosMx™ Spatial Molecular Imager, enabling the first high-plex in situ analysis platform to provide spatial multi-omics with formalin-fixed paraffin-embedded (FFPE) and fresh frozen (FF) tissue samples at cellular and subcellular resolution. CosMx SMI is a flexible, spatial single-cell imaging platform that will drive deeper insights for cell atlasing, tissue phenotyping, cell-cell interactions, cellular processes, and biomarker discovery. In 2022, AtoMx™ Spatial Informatics Platform (SIP), the only cloud-based, fully-integrated informatics platform for spatial biology, was also launched. In 2024, NanoString Technologies has been acquired by Bruker Corporation, a leading global provider of scientific instruments and solutions. This strategic acquisition marks the beginning of a promising new chapter for NanoString and our valued customer.

PathAI's mission is to improve patient outcomes with AI-powered pathology. Our platform promises substantial improvements to the accuracy of diagnosis and the efficacy of treatment of diseases like cancer, leveraging modern approaches in machine learning. We are a company of diverse employees with a wide range of backgrounds and experiences. Our world class team is passionate about solving challenging problems and making a huge impact. Our office is located in the heart of Fenway. PathAI was recently voted one of BBJ's Best Places to Work!

From discovery to diagnosis, the HALO® suite supports the full digital pathology journey. Indica Labs delivers AI-powered solutions spanning life science research, translational science, pharmaceutical development, companion diagnostics, and clinical deployment. Today, HALO has surpassed 3,000 deployments across 35 countries and six continents, supporting all 20 of the world’s top pharmaceutical companies and research cited in more than 2,600 peer-reviewed publications. That global research footprint is increasingly translating into clinical adoption, with HALO AP® clinical revenue growing 260% since 2023 and recurring clinical revenue increasing 200% year-over-year in 2025. From HALO®, HALO AI, and HALO Link to HALO AP® (CE-IVDR marked) and HALO AP Dx (FDA 510k cleared), one connected ecosystem helps bridge discovery, development, validation, and clinical implementation. One HALO ecosystem. From life science discovery to clinical deployment.